Tin tức & Cập nhật
Lọc theo Chuyên ngành:
Remibrutinib shows potential in chronic spontaneous urticaria
Treatment with remibrutinib, a novel oral inhibitor of Bruton’s tyrosine kinase, appears to be both safe and effective for the treatment of chronic spontaneous urticaria, a new study has found.
Remibrutinib shows potential in chronic spontaneous urticaria
21 Sep 2022Remote smoking cessation programme delivers encouraging results in high-risk individuals
A smoking cessation intervention delivered via telephone resulted in greater smoking cessation rates than usual care among individuals enrolled in targeted lung health screening, according to results of the QuLIT*2 study from the UK presented at ERS 2022.
Remote smoking cessation programme delivers encouraging results in high-risk individuals
20 Sep 2022Bimekizumab safety for moderate to severe plaque psoriasis affirmed
Treatment with bimekizumab for up to 2 years appears to be tolerated well in patients with moderate-to-severe plaque psoriasis, with no increased risk of adverse events (AEs) aside from a higher frequency of mild-to-moderate oral candidiasis, according to pooled analyses of data from eight randomized controlled trials (RCTs).
Bimekizumab safety for moderate to severe plaque psoriasis affirmed
20 Sep 2022Can extended duration tinzaparin improve survival in CRC?
Extended duration perioperative thromboprophylaxis with low molecular weight heparin tinzaparin (administered before and for 56 days after surgery) does not lead to longer disease-free survival at 3 years in patients with localized invasive colorectal cancer undergoing surgical resection, reports a study.
Can extended duration tinzaparin improve survival in CRC?
20 Sep 2022PDE5-I use poses no excess cardiovascular, mortality risk in diabetic men with ED
The presence of erectile dysfunction (ED) does not appear to confer an increased risk of cardiovascular disease (CVD) and mortality in men with diabetes mellitus (DM), with comparable risk of adverse cardiovascular events among users and nonusers of phosphodiesterase-5 inhibitors (PDE5-Is), which are used to manage ED, according to a study.